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way) suggested the largest driver of cost-effectiveness was the effect of irinotecan
dose reduction on survival. Value of information analysis indicated a low value of
future research to reduce parameter uncertainty (5 year population EVPI: £31,564).
However, assumptions affecting model structure had a relatively higher impact on
cost-effectiveness.CONCLUSIONS:This is the first economic evaluation of UGT1A1
testing to reduce the incidence of febrile neutropaenia. This study illustrated the
importance of considering febrile neutropaenia in addition to grade 3 and 4 neu-
tropaenia in evaluations of UGT1A1 testing.
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OBJECTIVES: Rituximab (Rmb), Imatinib (Imt) and extra-corporeal photopheresis
(ECP) are some of the strategies used as rescue therapy among patients with
chronic graft-versus-host disease (cGVHD) who failes previous lines of treatment.
The purpose of the study was to assess the cost-effectiveness of ECP in patients
with cGVHD in Spain. METHODS: A Microsimulation model was built to estimate
the clinical and economic consequences of ECP versus Rmb or Imt for 1000 hypo-
thetical patients. Model probabilities concerning the efficacy of ECP, Rtm and Imt
and severity degree per organ affected were obtained from literature. Treatment
pathways and adverse events were evaluated taking into consideration expert
opinion. Local data on costs (Euros 2010) and use of health resources were also
validated by clinical experts. An annual 3% discount rate was applied to costs and
outcomes. The perspective was the Spanish National Health System and time ho-
rizon was 5 years. RESULTS:Differences in improvement when ECP is used showed
a gain at first year of 6.2% and of 6.7% against Rmb and Imt, respectively. The higher
efficacy of ECP leads to a gain of 0.011–0.024 Quality Adjusted Life Year in the first
year and 0.062-0.094 at year five compared to Rmb or Imt. Results showed than
higher acquisition cost of ECP vs Imt was compensated at 9 months by higher
efficacy and vs Rmb was partially compensated (517€ year 5). After 9 months, ECP
was dominant vs Imt. The incremental cost-effectiveness ratio of ECP versus Rmb
was 29,646€ per LY gained and 24,442 € per QALY gained at year 2.5. The probabi-
listic sensitivity analysis show robustness of results, being the ECP cost-effective in
70% of the simulated cases at year 5 (threshold of €30,000 per QALY gained).
CONCLUSIONS: ECP as third-line therapy for cGVHD is a more cost-effective com-
pared to Rmb or Imt.
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OBJECTIVES: The UGT1A1 pharmacogenetic test can potentially inform irinotecan
dose selection and reduce the incidence of neutropaenia, a key adverse event of
irinotecan-based chemotherapy in advanced colorectal cancer (CRC). Neutropae-
nia has a negative impact on health and its management uses healthcare re-
sources. The UGT1A1 test identifies patients at low-, intermediate- or high-risk of
grade 3&4 neutropaenia. High-risk patients can be prescribed lower doses to reduce
the incidence of neutropaenia. This study aimed to assess the cost-effectiveness of
UGT1A1 testing and identify key parameters driving cost-effectiveness.METHODS:
An economic model of UGT1A1 testing to predict grade 3&4 neutropaenia com-
pared to standard care was developed over a lifetime horizon from the UK NHS
perspective. Treatment pathways were informed by a national survey of CRC ex-
perts (n44). The model was populated with data from: systematic reviews of the
effectiveness and utility literature; a micro-costing observational study (n48 pa-
tients) and CRC expert (n55) elicitation. RESULTS: UGT1A1 testing was cost-sav-
ing and resulted in lower incidence of grade 3&4 neutropaenia. For a cohort of 100
patients, the test was estimated to save £14,500, avoid 4.4 neutropaenic episodes,
gain 0.06 life-years and 0.05 QALYs. The probability that the test was cost-effective
at willingness-to-pay thresholds between £20,000 and £30,000 per QALY gained
was above 95%. These findings were specific to model assumptions and specifica-
tions. Sensitivity analysis (probabilistic and one-way) suggested that the main
driver of cost-effectiveness was the effect of irinotecan dose reduction on survival.
Value of information analysis indicated a low value of future research to reduce
parameter uncertainty (5 year population EVPI: £13,116). In contrast, assumptions
affecting model structure had a comparatively greater impact on
cost-effectiveness. CONCLUSIONS: This analysis modelled NHS-relevant clinical
treatment pathways and provided potentially useful evidence for UK decision-
makers. Structural model assumptions rather than parameter inputs had a larger
impact on cost-effectiveness.
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OBJECTIVES: Aortic valve stenosis is a chronic and progressive valvular heart dis-
ease. The standard treatment of this condition involves a major open surgery. For
patients currently ineligible for surgery, medical management is the only option
available. Transcatheter aortic valve implantation (TAVI) devices recently ap-
peared as a new less invasive treatment option. The objective of this study was to
develop an exploratory cost-effectiveness analysis of TAVI vs Optimal Medical
Treatment (OMT) in the Portuguese Setting. METHODS: This analysis used a
Markov model developed by Oxford Outcomes to assess costs and benefits of TAVI
vs OMT. A short term sub-model represents the first 30 days after TAVI (cycle
length of one day), whereas a long term model (cycle length of one month) consid-
ers a 10-year time horizon. For TAVI patients the health states considered are ICU,
General Wards, Home, Re-operation and Death. OMT patients are in either Home or
Dead health states, receiving medication until death and at risk of co-morbidity-
related hospitalisations. Portuguese NHS healthcare resource consumption was
retrospectively collected at Hospital de Santa Cruz in Lisbon for a cohort of 44 high
risk AS patients (21 TAVI; 23 OMT), over a period of 11 months. Clinical parameters,
transition probabilities and utility values were derived from relevant literature.
Costs were taken from the official Portuguese published tables and hospital re-
ports. Costs and benefits were discounted at 5% p.a. Probabilistic and one-way
sensitivity analysis were performed. RESULTS: Treatment with TAVI compared to
OMT increased life years by 1.7 (3.13 vs. 1.46) and quality-adjusted life years
(QALYs) by 1.4 (2.23 vs. 0.80). Direct costs were 32,067€ with TAVI and 4,662€ with
OMT. Incremental Cost Effectiveness Ratios (ICERs) estimated are 16,375 € /LYG and
19,180 € /QALY. CONCLUSIONS: TAVI is highly likely to be a cost-effective inter-
vention for the treatment of AS in patients who are currently ineligible for surgery.
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OBJECTIVES: In Hungary the re-regulated, transparent coverage system of medical
aids was put into force in 2007 (after the re-regulation of coverage policy of drugs
/2004/). Until 2010 287 reimbursement applications were evaluated by the Office of
HTA of the National Institute for Strategic Health Research. The aim of the study
was to develop a standard reimbursement dossier, which evidenced the effective-
ness and cost-effectiveness of a new medical device (Nebulizer Mini-Plus).
METHODS:According to a recommendation of the above mentioned HTA Office the
combined assessment of technical functions and prices was suggested as eligible
filter for the coverage of products with sufficient price-value rate. Hence the base of
the study was: to compare the technical parameters of nebulizers and to use the
cost-minimization analysis (CM). The study had payer’s perspective, but aspect of
equity (burden of disease) was taken into consideration because of the high signif-
icance of diseases of respiratory system. After the literature review and compari-
son of technical parameters of nebulizers, the 2009-2010 turnover of nebulizers
were analysed and the budget impact was estimated for 2011-2012, considering the
business risks. RESULTS: Taking into consideration that several technical param-
eters (lung deposition, particle size) of Mini-Plus exceeded other devices and its
price was lower than the cheapest reimbursed device: it was expressed as the
dominant alternative of compression nebulizer therapies. By its coverage the payer
can reach almost 15.000 USD saving and minimally 3685 USD burden loss (reducing
of co-payment) for patients until 2012. There are additionally cost-saving poten-
tials in reduction of drug consumption and hospitalization. CONCLUSIONS: The
combined assessment of technical functions and prices (supported by CM) was a
successful and eligible strategy for the evaluation of the effectiveness and cost-
effectiveness of a new medical device, and can be adapted for other types of med-
ical aids.
PMD48
AN ECONOMIC EVALUATION OF THE HEARTWARE VENTRICULAR ASSIST
DEVICE IN THE NHS
Craig J1, Saxby RC1, Homer T2, Swartz MT2
1University of York, Heslington, York, UK, 2HeartWare Inc., Framingham, MA, USA
OBJECTIVES: End-stage heart failure is a leading cause of death; patients have a
poor prognosis and low quality of life. Managing the limiting and distressing symp-
toms places significant costs on the NHS. Therapy options are few; primarily com-
bination medical therapy and, for a few patients, transplantation using a donor
heart. Left ventricular assist devices (LVADs) are mechanical pumps that support
the heart function. Use is increasing worldwide as more studies demonstrate clin-
ical effectiveness, primarily from improved patient survival and quality of life.
However, there are no published cost effectiveness studies. This pilot evaluates the
cost effectiveness of the HeartWare LVAD as destination therapy for patients with
end-stage heart failure. METHODS: A cost-utility model compared the outcomes
and costs of patients who were medically managed without a transplant (n15)
with those who received a HeartWare LVAD and no subsequent transplant (n17).
Clinical data were from a multicentre trial evaluating the safety and efficacy of the
HeartWare LVAD [1] and outcomes for patients listed on the NHS Blood and Trans-
plant Registry [2]. Utility values were from a Health Technology Assessment [3] and
derived using the EQ-5D tool. Cost data came mainly from published sources.
RESULTS: The results from this evaluation were patients managed with the Heart-
Ware device had higher costs but better outcomes than those who were medically
managed. At 5 years the additional cost was about £20,500 per patient and a QALY
gain of 1.05, giving an incremental cost per QALY of under £20,000, below the
threshold commonly adopted of £25,000 per QALY. CONCLUSIONS: The results are
encouraging and suggest it is plausible that using LVADs as long-term support in
patients with end-stage heart failure could be a cost-effective use of healthcare
provider resources. Further research is needed to refine the clinical and cost data.
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